Unmet Needs in Dermatology: EC Approves Mirdametinib (Ezmekly, SpringWorks Therapeutics, Inc.) for NF1-PN in Children and Adults
The European Commission (EC) granted conditional marketing authorization for mirdametinib (Ezmekly, SpringWorks Therapeutics, Inc.) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in pediatric and adult patients with neurofibromatosis type 1 (NF1) aged two and older.